SCHEMBL4164409

SCHEMBL4164409

[O-][n+]1cc(O)cc2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATM Q13315 3/20 0.50
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
POLB P06746 1/20 0.44
CASP6 P55212 1/20 0.44
CYP1A2 P05177 1/20 0.41
NQO2 P16083 1/20 0.38
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
MPI P34949 1/20 0.33
RAB9A P51151 1/20 0.33
ESR1 P03372 3/20 0.32
ESR2 Q92731 3/20 0.32
NPC1 O15118 1/20 0.32
PARP1 P09874 1/20 0.31
HSD17B1 P14061 1/20 0.31
HSD17B2 P37059 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1285478 0.75 ATM (0.50) ATMMEN1KMT2APOLBCASP6
SCHEMBL13806417 0.75 ATM (0.50) ATMMEN1KMT2APOLBCASP6
SCHEMBL8512795 0.75 ATM (0.50) ATMMEN1KMT2APOLBCASP6
SCHEMBL1394239 0.75 ATM (0.50) ATMMEN1KMT2APOLBCASP6
SCHEMBL2796407 0.75 ATM (0.50) ATMMEN1KMT2ACYP1A2KDM4E
SCHEMBL25413825 0.75 ATM (0.50) ATMMEN1KMT2APOLBCASP6
SCHEMBL7479947 0.75 ATM (0.50) ATMMEN1KMT2APOLBCASP6
SCHEMBL21988773 0.75 ERN1 (0.34) MEN1KMT2APOLBCASP6KDM4E
SCHEMBL3264399 0.73 MEN1 (0.47) ATMMEN1KMT2APOLBCASP6
SCHEMBL2008748 0.73 PARP1 (0.50) ATMMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163088-A1 HALF-SANDWICH TRANSITION METAL COMPLEXES AND USES THEREOF DEBRECENI EGYETEM (HU) 2025-05-22 US disclosed
EP-4463230-A1 HALF-SANDWICH TRANSITION METAL COMPLEXES AND USES THEREOF Debreceni Egyetem (HU) 2024-11-20 EP disclosed
US-11987589-B2 Heterocyclic flavone derivatives, compositions, and methods related thereto EMORY UNIVERSITY (US) 2024-05-21 US disclosed
EP-4344743-A2 HETEROCYCLIC FLAVONE DERIVATIVES, COMPOSITIONS, AND METHODS RELATED THERETO Emory University (US) 2024-04-03 EP disclosed
EP-3833343-B1 HETEROCYCLIC FLAVONE DERIVATIVES, COMPOSITIONS, AND METHODS RELATED THERETO UNIV EMORY (US) 2024-02-21 EP disclosed
WO-2023041947-A1 HALF-SANDWICH TRANSITION METAL COMPLEXES AND USES THEREOF DEBRECENI EGYETEM (HU) 2023-03-23 WO disclosed
US-20210292335-A1 Heterocyclic Flavone Derivatives, Compositions, and Methods Related Thereto EMORY UNIVERSITY 2021-09-23 US disclosed
CN-107868071-B 7, 8-dihydroxyflavone and 7, 8-substituted flavone derivatives, compositions, and methods related thereto 爱默蕾大学 2021-07-20 CN disclosed
EP-3833343-A1 HETEROCYCLIC FLAVONE DERIVATIVES, COMPOSITIONS, AND METHODS RELATED THERETO Emory University (US) 2021-06-16 EP disclosed
EP-3369730-B1 7,8-DIHYDOXYFLAVONE AND 7,8-SUBSTITUTED FLAVONE DERIVATIVES, COMPOSITIONS, AND METHODS RELATED THERETO UNIV EMORY (US) 2020-08-05 EP disclosed
EP-0942723-B1 4-ARYL-3-HYDROXYQUINOLIN-2-ONE DERIVATIVES AS ION CHANNEL MODULATORS BRISTOL MYERS SQUIBB CO (US) 2004-01-21 EP disclosed
EP-0942723-A4 4-ARYL-3-HYDROXYQUINOLIN-2-ONE DERIVATIVES AS ION CHANNEL MODULATORS BRISTOL MYERS SQUIBB CO (US) 2002-05-15 EP disclosed
EP-1011677-A4 4-ARYL-3-AMINOQUINOLINE-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS BRISTOL MYERS SQUIBB CO (US) 2002-03-20 EP disclosed
EP-1011677-A1 4-ARYL-3-AMINOQUINOLINE-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS Bristol-Myers Squibb Company (US) 2000-06-28 EP disclosed
US-5972961-A ANTIISCHEMIC AGENTS; ANTICONVULSANTS; HEADACHES; SEXUAL DISORDERS BRISTOL-MYERS SQUIBB COMPANY (US) 1999-10-26 US disclosed
EP-0942723-A1 4-ARYL-3-HYDROXYQUINOLIN-2-ONE DERIVATIVES AS ION CHANNEL MODULATORS Bristol-Myers Squibb Company (US) 1999-09-22 EP disclosed
US-5922735-A CALCIUM-ACTIVATED POTASSIUM CHANNELS AND ARE USEFUL TREATING THE DISORDER RESPONSIVE TO THE OPENING OF THE POTASSIUM CHANNELS SUCH AS ISCHEMIA, CONVULSIONS, ASTHMA, IRRITABLE BOWEL SYNDROME, MIGRAINE, TRAUMATIC BRAIN INJURY BRISTOL-MYERS SQUIBB COMPANY (US) 1999-07-13 US disclosed
US-5892045-A 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators BRISTOL-MYERS SQUIBB COMPANY (US) 1999-04-06 US disclosed
WO-1999009983-A1 4-ARYL-3-AMINOQUINOLINE-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 1999-03-04 WO disclosed
WO-1998023273-A1 4-ARYL-3-HYDROXYQUINOLIN-2-ONE DERIVATIVES AS ION CHANNEL MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 1998-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11987589-B2 Heterocyclic flavone derivatives, compositions, and methods related thereto BDNF, NTRK2, RHOT2 ATM 3615/4885MEN1 2217/4885KMT2A 588/4885
US-20250163088-A1 HALF-SANDWICH TRANSITION METAL COMPLEXES AND USES THEREOF SLC39A3, CUTA, SLC30A6 ATM 4191/4885MEN1 232/4885KMT2A 3061/4885
US-20210292335-A1 Heterocyclic Flavone Derivatives, Compositions, and Methods Related Thereto BDNF, NTRK2, RHOT2 ATM 3615/4885MEN1 2217/4885KMT2A 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.